argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
argenx SE - American Depositary Shares (ARGX)
US:NASDAQ Investor Relations:
investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
Company Research
Source: GlobeNewswire
ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP September 19, 2024 – 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced publication in The Lancet Neurology of the pivotal ADHERE Study, the largest clinical trial to date in chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a rare, debilitating, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system. This is the first time the ADHERE Study has been published in a peer-reviewed medical journal. A link to the full manuscript can be found here. “S
Show less
Read more
Impact Snapshot
Event Time:
ARGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting argenx SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ARGX
News
- argenx SE (NASDAQ: ARGX) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $697.00 price target on the stock.MarketBeat
- argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in ChinaGlobeNewswire
- argenx SE (NASDAQ: ARGX) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $715.00 price target on the stock.MarketBeat
- argenx SE (NASDAQ: ARGX) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $715.00 price target on the stock.MarketBeat
- argenx to Participate at Upcoming Investor ConferencesGlobeNewswire
ARGX
Earnings
- 10/31/24 - Beat
ARGX
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- 11/12/24 - Form 6-K
- ARGX's page on the SEC website